IL2 and systemic lupus erythematosus: Notably, therapeutic administration of JES6/IL-2 complexes in a spontaneous model of lupus was shown to ameliorate ICGN (45), arguing in favor for our hypothesis that stimulation of donor CD4+ T cells by JES6/IL-2 complexes canceled out the beneficial effect of Treg stimulation.